Life Science

Più recente

281 a 290 di 571
  • Social Media: legal pitfalls Accesso limitato

    Articolo

    Inviato: 15 March 2013

    Regulation on use of social media for advertising medicines.

  • Clinical Trials: reshaping the European regime Accesso limitato

    Articolo

    Inviato: 15 March 2013

    EU clinical trials regulation changes.

  • Unified Patent Court - what patentees need to know Accesso limitato

    Articolo

    Inviato: 14 March 2013

    What do patentees need to consider now to be ready to take advantage of new Unified Patent Court when it comes into force. This article forms part of our Unified Patent Court Toolkit.

  • France: the Bertrand Law Accesso limitato

    Articolo

    Inviato: 13 March 2013

    Changes in French public health regulation.

  • Pharmaceutical Parallel Imports – A Step Too Far?

    Articolo

    Inviato: 07 March 2013

    Senior industry figures call for an end to parallel trade in pharmaceuticals.

  • Communicating with consumers: rules in the EU Accesso limitato

    Articolo

    Inviato: 07 March 2013

    Existing Community legislation strictly prohibits advertising prescription only medicines to the general public. As noted by the European Court of Justice, Community legislation has brought about harmonisation of the rules on advertising of medicinal products from which Member States have no discretion to deviate.

  • Pharmacovigilance: an overhaul Accesso limitato

    Articolo

    Inviato: 07 March 2013

    Amendments to the legislative framework on pharmacovigilance have been approved. An initial set of rules were introduced in July 2012 and this second set of changes will be applicable by the end of 2013. Marketing authorisation holders are going to have to make significant changes to their pharmacovigilance systems.

  • SPCs: the Dr Reddy’s Case Accesso limitato

    Articolo

    Inviato: 07 March 2013

    On 20 Dec 2012, the Patents Court of England and Wales rejected a challenge brought by Dr Reddy’s Laboratories against the paediatric extension of Pfizer’s Supplementary Protection Certificate for its existing cholesterol product atorvastatin (marketed as Lipitor.

  • Proposals to revise the competition rules for licensing agreements unveiled

    Articolo

    Inviato: 04 March 2013

    The Commission has published proposals for a revised technology transfer regime and invites comments from stakeholders.

  • Still a postcode lottery? Enforcing implementation of NICE technology appraisals Accesso limitato

    Articolo

    Inviato: 28 February 2013

    This article reviews the legal position of NICE technology appraisal guidance. It considers problems with its consistent implementation and the potential response of the pharmaceutical industry.

281 a 290 di 571